-
Dosimetry Software for Theranostic Applications: Current Capabilities and Future Prospects J Nucl. Med. (IF 9.1) Pub Date : 2025-01-08
Adam L. Kesner, Julia Brosch-Lenz, Jonathan Gear, Michael LassmannDosimetry is integral to informed implementation of radiopharmaceutical therapies, enabling personalized treatment planning and ensuring patient safety by calculating absorbed doses to organs and tumors. As the therapeutic radiopharmaceutical field continues to expand, dosimetry software has emerged as a crucial tool for optimization of treatment efficacy. This review discusses key features and capabilities
-
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup J Nucl. Med. (IF 9.1) Pub Date : 2025-01-08
Gil D. Rabinovici, David S. Knopman, Javier Arbizu, Tammie L.S. Benzinger, Kevin J. Donohoe, Oskar Hansson, Peter Herscovitch, Phillip H. Kuo, Jennifer H. Lingler, Satoshi Minoshima, Melissa E. Murray, Julie C. Price, Stephen P. Salloway, Christopher J. Weber, Maria C. Carrillo, Keith A. JohnsonThe Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the
-
177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial J Nucl. Med. (IF 9.1) Pub Date : 2025-01-08
Swayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood, Kunal R. Chandekar, Chandan K. Das, Rajesh Gupta, Divya Khosla, Namrata Das, Rakesh Kapoor, Rajender Kumar, Harmandeep Singh, Jaya Shukla, Ajay Kumar, Bhagwant Rai Mittal177Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant 177Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials. Methods: In this i
-
Prospective Head-to-Head Comparison of 18F-PSMA PET/CT and 18F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer J Nucl. Med. (IF 9.1) Pub Date : 2025-01-08
Claus Madsen, Dan Fuglø, Maria Pedersen, Rikke Broholm, Peter B. Østergren, Rasmus Bisbjerg, Per Kongsted, Kayalvili Nielsen, Christian Haarmark, Helle ZachoVisual Abstract
-
2024 SNMMI Highlights Lecture: General Clinical Specialties J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Twyla BartelThe Highlights Lecture, presented at the closing session of each SNMMI Annual Meeting, was originated and presented for more than 30 y by Henry N. Wagner, Jr., MD. Beginning in 2010, the duties of summarizing selected significant presentations at the meeting were divided annually among 4 distinguished nuclear and molecular medicine subject matter experts. The 2024 Highlights Lectures were delivered
-
Quantitative Accuracy Assessment of the NeuroEXPLORER for Diverse Imaging Applications: Moving Beyond Standard Evaluations J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Negar Omidvari, Ekaterina Shanina, Edwin K. Leung, Xishan Sun, Yusheng Li, Tim Mulnix, Paul Gravel, Shannan Henry, David Matuskey, Tommaso Volpi, Terry Jones, Ramsey D. Badawi, Hongdi Li, Richard E. Carson, Jinyi Qi, Simon R. CherryQuantitative molecular imaging with PET can offer insights into physiologic and pathologic processes and is widely used for studying brain disorders. The NeuroEXPLORER is a recently developed dedicated brain PET system offering high spatial resolution and high sensitivity with an extended axial length. This study evaluated the quantitative precision and accuracy of the NeuroEXPLORER with phantom and
-
Effect of Acute Hypoxia Exposure on the Availability of A1 Adenosine Receptors and Perfusion in the Human Brain J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Manuel Michno, Jan Schmitz, Anna L. Foerges, Simone Beer, Jens Jordan, Bernd Neumaier, Alexander Drzezga, Daniel Aeschbach, Andreas Bauer, Jens Tank, Henning Weis, Eva-Maria Elmenhorst, David ElmenhorstIn animal studies it has been observed that the inhibitory neuromodulator adenosine is released into the cerebral interstitial space during hypoxic challenges. Adenosine’s actions on the A1 adenosine receptor (A1AR) protect the brain from oxygen deprivation and overexertion through adjustments in cerebral blood flow, metabolism, and electric activity. Methods: Using 8-cyclopentyl-3-(3-[18F]fluorop
-
Myelin Imaging of the Spinal Cord in Animal Models and Patients with Multiple Sclerosis Using [11C]MeDAS PET: A Translational Study J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Chris W.J. van der Weijden, Ahmed K.M.A. Ahmed, Anouk van der Hoorn, Junqing Zhu, Chunying Wu, Yanming Wang, Gilles N. Stormezand, Rudi A.J.O. Dierckx, Jan F. Meilof, Erik F.J. de VriesMultiple sclerosis (MS) is a neurodegenerative disease characterized by demyelinated lesions in the brain and spinal cord. A few clinical studies using PET to image myelin in the brain have been performed, but none investigated the spinal cord. Because clinically relevant motor symptoms are primarily due to spinal cord damage, this translational study evaluated [11C]N-methyl-4,4'-diaminostilbene (MeDAS)
-
Antibody-Based PET Imaging of Misfolded Superoxide Dismutase 1 in an Amyotrophic Lateral Sclerosis Mouse Model J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Jacques A. Rousseau, Marcel Maier, Samia Ait-Mohand, Véronique Dumulon-Perreault, Otman Sarrhini, Sébastien Tremblay, Etienne Rousseau, Michael Salzmann, Brigitte GuérinAmyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease characterized by motor neuron loss in the motor cortex, brain stem, and spinal cord. Mutations in the superoxide dismutase 1 (SOD1) gene, resulting in misfolding of its protein product, are a common cause of ALS. Currently, there is no approved ALS diagnostic tool. Here, we present the development of a PET radiotracer, [89Zr]Zr-desferoxamine
-
Comparison Between Brain and Cerebellar Autoradiography Using [18F]Flortaucipir, [18F]MK6240, and [18F]PI2620 in Postmortem Human Brain Tissue J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Antonio Aliaga, Joseph Therriault, Kely Monica Quispialaya, Arturo Aliaga, Robert Hopewell, Nesrine Rahmouni, Arthur C. Macedo, Peter Kunach, Jean-Paul Soucy, Gassan Massarweh, Aida Abreu Diaz, Tharick A. Pascoal, Andreia Rocha, Marie-Christine Guiot, Luiza S. Machado, Marco Antônio De Bastiani, Débora Guerini de Souza, Diogo O. Souza, Serge Gauthier, Eduardo R. Zimmer, Pedro Rosa-NetoOur objective was to evaluate the in vitro binding properties of [18F]flortaucipir, 6-(fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]MK6240), and 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5c′]dipyridine ([18F]PI2620) head-to-head in postmortem human brain tissue. Methods: Autoradiography was used to assess uptake of [18F]flortaucipir, [18F]MK6240, and [18F]PI2620 in
-
[11C]PS13 Demonstrates Pharmacologically Selective and Substantial Binding to Cyclooxygenase-1 in the Human Brain J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Nafiseh Ghazanfari, Jeih-San Liow, Min-Jeong Kim, Raven Cureton, Adrian Lee, Carson Knoer, Madeline Jenkins, Jinsoo Hong, Jose A. Montero Santamaria, H. Umesha Shetty, Anthony Galassi, Paul Wighton, Martin Nørgaard, Douglas N. Greve, Sami S. Zoghbi, Victor W. Pike, Robert B. Innis, Paolo Zanotti-FregonaraOur laboratory recently developed [11C]PS13 as a PET radioligand to selectively measure cyclooxygenase-1 (COX-1). The cyclooxygenase enzyme family converts arachidonic acid into prostaglandins and thromboxanes, which mediate inflammation. The total brain uptake of [11C]PS13, which is composed of both specific binding and background uptake, can be accurately quantified with gold standard methods of
-
Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Lyduine E. Collij, Gérard N. Bischof, Daniele Altomare, Ilse Bader, Mark Battle, David Vállez García, Isadora Lopes Alves, Robin Wolz, Rossella Gismondi, Andrew Stephens, Zuzana Walker, Philip Scheltens, Agneta Nordberg, Juan Domingo Gispert, Alexander Drzezga, Andrés Perissinotti, Silvia Morbelli, Christopher Buckley, Valentina Garibotto, Giovanni B. Frisoni, Gill Farrar, Frederik BarkhofSeveral studies have demonstrated strong agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support assessment by less experienced readers or in challenging cases. However, all studies to date have implemented a retrospective case collection, and challenging cases were generally underrepresented. Methods: We included all participants
-
Comparability of Quantifying Relative Lung Ventilation with Inhaled 99mTc-Technegas and 133Xe in Patients Undergoing Evaluation for Lung Transplantation J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Ashwin Singh Parihar, Joyce C. Mhlanga, Henry D. Royal, Barry A. Siegel99mTc-Technegas was recently approved by the U.S. Food and Drug Administration as a radiopharmaceutical for ventilation scintigraphy. However, there are currently no data comparing the quantification of relative lung ventilation with 99mTc-Technegas with that performed using the standard approach with inhaled 133Xe. Methods: We performed a secondary analysis of data from prospectively recruited participants
-
Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Peng Hou, Haiming Chen, Sihao Liang, Wenliang Guo, Ruiyue Zhao, Huailu Pan, Haimin Liu, Youcai Li, Jie Lv, Kaixiang Zhong, Miao Ke, Yimin Fu, Huizhen Zhong, Xinlu Wang, Cheng HongThe purpose of this study was to investigate the feasibility of using 18F-labeled fibroblast activation protein inhibitor (FAPI) PET/CT in assessing the fibrotic remodeling of the pulmonary artery (PA) and the right ventricle (RV) in pulmonary arterial hypertension (PAH). Methods: In a rat model of monocrotaline-induced PAH, rats were euthanized at different time points for tissue analysis (fibroblast
-
Localized In Vivo Prodrug Activation Using Radionuclides J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Jeremy M. Quintana, Fangchao Jiang, Mikyung Kang, Victor Valladolid Onecha, Arda Könik, Lei Qin, Victoria E. Rodriguez, Huiyu Hu, Nicholas Borges, Ishaan Khurana, Leou I. Banla, Mariane Le Fur, Peter Caravan, Jan Schuemann, Alejandro Bertolet, Ralph Weissleder, Miles A. Miller, Thomas S.C. NgRadionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically activate prodrugs at disease sites while avoiding activation in off-target sites of toxicity. As proof of principle, we tested whether this strategy of radionuclide-induced drug
-
Mathematic Modeling of Tumor Growth During [177Lu]Lu-PSMA Therapy: Insights into Treatment Optimization J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Nouran R.R. Zaid, Remco Bastiaannet, Rob Hobbs, George SgourosThe treatment regimen for [177Lu]Lu-prostate-specific membrane antigen (PSMA) 617 therapy follows that of chemotherapy: 6 administrations of a fixed activity, each separated by 6 wk. Mathematic modeling can be used to test the hypothesis that the current treatment regimen for a radiopharmaceutical modality is suboptimal. Methods: A mathematic model was developed to describe tumor growth during [177Lu]Lu-PSMA
-
Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Sean R. Miller, Rachel Tucker Gonzalez, William C. Jackson, Megan E.V. Caram, Phoebe A. Tsao, Kristian Stensland, Yashesh Shah, Daniel Wale, Ka Kit Wong, Benjamin L. Viglianti, David Elliott, Tanner Caverly, Timothy P. Hofer, Sameer Saini, Michael D. Green, Matthew Schipper, Robert T. Dess, Alex K. BryantProstate-specific membrane antigen (PSMA) PET was approved by the U.S. Food and Drug Administration in 2020 for the staging of newly diagnosed prostate cancer, yet rates of adoption and real-world positivity rates are unknown. We characterized patients undergoing PSMA PET staging and describe positive findings in a large national cohort. Methods: We identified all newly diagnosed prostate cancer patients
-
Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Lilit Schweiger, Tobias Maurer, Ricarda Simon, Thomas Horn, Matthias Heck, Wolfgang A. Weber, Matthias Eiber, Isabel RauscherProstate-specific membrane antigen (PSMA)–targeted radioguided surgery (RGS) is evolving as a new treatment modality for patients with early biochemical recurrence of prostate cancer and disease limited to locoregional lymph nodes on PSMA-ligand PET/CT. Nevertheless, the pattern of failure (locoregional vs. systemic) after PSMA RGS remains unknown. Therefore, the aim of this retrospective analysis
-
Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Mike Wenzel, Florestan Koll, Benedikt Hoeh, Clara Humke, Carolin Siech, Nicolai Mader, Amir Sabet, Daniel Groener, Thomas Steuber, Markus Graefen, Tobias Maurer, Christian Brandts, Severine Banek, Felix K.H. Chun, Philipp Mandel177Lu-vipivotide tetraxetan prostate-specific membrane antigen (177Lu-PSMA) therapy is under current scientific investigation and aims to become established in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, real-world evidence in treatment comparison is scant. Methods: We relied on the FRAMCAP database and compared cabazitaxel versus 177Lu-PSMA therapy in mCRPC patients
-
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Lena M. Unterrainer, Thomas A. Hope, Wolfgang P. Fendler, Tristan Grogan, Honest Ndlovu, Wesley Armstrong, Francesco Barbato, Matthias R. Benz, Matthew B. Rettig, Amar U. Kishan, Mike Sathekge, Ken Herrmann, Johannes Czernin, Jeremie CalaisHigh-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria. HVD and LVD definitions are associated with overall survival and are used for treatment decisions. It remains unknown how these definitions transfer to prostate-specific
-
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG–Avid Discordant Findings J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Ridvan Arda Demirci, Alireza Ghodsi, Roman Gulati, Sanaz Behnia, Peter S. Nelson, Heather H. Cheng, Todd A. Yezefski, Michael C. Haffner, Jessica E. Hawley, Robert B. Montgomery, Evan Y. Yu, Michael T. Schweizer, Delphine L. Chen, Amir IravaniThe VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with 177Lu-PSMA-617 (LuPSMA). TheraP used a higher prostate-specific membrane antigen (PSMA) uptake threshold than VISION and required 18F-FDG PET to exclude patients with discordant findings. Although the screen-failed patients had shorter overall survival (OS) than those treated with LuPSMA, it
-
Preclinical Evaluation and Pilot Clinical Study of CD137 PET Radiotracer for Noninvasive Monitoring Early Responses of Immunotherapy J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Kai Cheng, Luna Ge, Miaomiao Song, Wanhu Li, Jinsong Zheng, Jingru Liu, Yuxi Luo, Pengfei Sun, Shengnan Xu, Zhen Cheng, Jinming Yu, Jie LiuGiven the variability in the effectiveness of immune checkpoint blocking therapy among patients and tumor types, development of noninvasive methods for longitudinal assessment of immune cell function and early tumor response is crucial for precision immunotherapy. CD137 (4-1BB), a marker of activated T cells, plays a significant role in immunotherapy. However, its potential as an imaging biomarker
-
[18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Joanna K. Weeks, Austin R. Pantel, Sarah B. Gitto, Fang Liu, Erin K. Schubert, Daniel A. Pryma, Michael D. Farwell, David A. Mankoff, Robert H. Mach, Fiona Simpkins, Lilie L. LinPoly(adenosine diphosphate–ribose) polymerase-1 (PARP1) inhibitors have improved ovarian cancer treatment outcomes. However, clinical response remains heterogeneous. Existing biomarkers, mainly breast cancer susceptibility genes 1 and 2 (BRCA1/2), are suboptimal. New tools are needed to guide patient selection. In this study, [18F]fluorthanatrace ([18F]FTT), a PET radiotracer for imaging PARP1, was
-
Molecular Imaging of Cancer Stem Cells and Their Role in Therapy Resistance J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Sofia N. dos Santos, Timothy H. WitneyDespite recent therapeutic breakthroughs, cancer patients continue to face high recurrence and mortality rates due to treatment resistance. Cancer stem cells (CSCs), a subpopulation with self-renewal capabilities, are key drivers of refractive disease. This review explores the application of molecular imaging techniques, such as PET and SPECT, for the noninvasive detection of CSCs. By providing real-time
-
Nuclear Cardiology Surrogate Biomarkers in Clinical Trials J Nucl. Med. (IF 9.1) Pub Date : 2025-01-01
Robert J.H. Miller, Krishna K. Patel, Jacek Kwiecinski, Leandro Slipczuk, Marc Dweck, David E. Newby, Panithaya Chareonthaitawee, Piotr SlomkaNuclear cardiology offers a diverse range of imaging tools that provide valuable insights into myocardial perfusion, inflammation, metabolism, neuroregulation, thrombosis, and microcalcification. These techniques are crucial not only for diagnosing and managing cardiovascular conditions but also for gaining pathophysiologic insights. Surrogate biomarkers in nuclear cardiology, represented by detectable
-
In Vivo Head-to-Head Comparison of [18F]GTP1 with [18F]MK-6240 and [18F]PI-2620 in Alzheimer Disease J Nucl. Med. (IF 9.1) Pub Date : 2025-01-02
Emily Olafson, Matteo Tonietto, Gregory Klein, Edmond Teng, Andrew W. Stephens, David S. Russell, Karen Pickthorn, Sandra Sanabria BohorquezVisual Abstract
-
Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure J Nucl. Med. (IF 9.1) Pub Date : 2025-01-02
Toshihiko Goto, Shohei Kikuchi, Yomei Sakurai, Yoshiro Tsuruta, Kento Mori, Tatsuya Mizoguchi, Yu Kawada, Yasuhiro Shintani, Masashi Yokoi, Sayuri Yamabe, Tsuyoshi Ito, Shuichi Kitada, Hidekatsu Fukuta, Kyoko Matsui, Hitomi Narita, Sumire Nankou, Yoshihiro SeoChronotropic incompetence (CTI), the inability of the heart to increase its rate with increased activity, leads to exercise intolerance and predicts overall mortality. We previously reported that cardiac β-adrenergic receptor downregulation occurs in patients with CTI without heart failure (HF), indicating postsynaptic sympathetic nervous dysfunction. However, cardiac presynaptic sympathetic nervous
-
Preserved Serotonin Transporter Availability in Parkinson Disease Measured with Either [11C]MADAM or [11C]DASB: A Study Including 2 Separate Cohorts of Nondepressed Patients J Nucl. Med. (IF 9.1) Pub Date : 2025-01-02
Minyoung Oh, Joachim Brumberg, Vesna Sossi, Andrea VarroneSerotonin transporter (SERT) availability was assessed using 2 tracers, [11C]N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine ([11C]DASB) and [11C]N,N-dimethyl-2-(2-amino-4-fluoromethylphenylthio)benzylamine) ([11C]MADAM), in independent cohorts of patients and controls. This study aimed to independently confirm whether SERT remains intact in nondepressed individuals with early-stage Parkinson
-
Longitudinal Trajectory of Dopamine and Serotonin Transporters in Parkinson Disease J Nucl. Med. (IF 9.1) Pub Date : 2025-01-02
Yujin Song, Jae-Hyeok Lee, Han-Kyeol Kim, Jae Hoon Lee, Young Hoon Ryu, Han Soo Yoo, Chul Hyoung LyooParkinson disease (PD) is a multisystem disorder marked by progressive dopaminergic neuronal degeneration in the substantia nigra, as well as nondopaminergic systems. Our aim was to investigate longitudinal changes in N-(3-[18F]fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (18F-FP-CIT) binding at the putamen, substantia nigra, and raphe nuclei in PD. Methods: This retrospective cohort study
-
First-in-Human Study of [11C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain J Nucl. Med. (IF 9.1) Pub Date : 2025-01-02
Aya Ogata, Hiroshi Ikenuma, Fumihiko Yasuno, Takashi Nihashi, Saori Hattori, Yayoi Sato, Masanori Ichise, Kengo Ito, Takashi Kato, Yasuyuki KimuraMicroglia, the immune cells in the brain, play a significant role in the pathophysiology of neurodegenerative diseases. To visualize these cells in the living brain, we developed a PET ligand, [11C]NCGG401 (4-{2-[((1R,2R)-2-hydroxycyclohexyl)(methyl)amino]benzothiazol-6-yloxy}-N-methylpicolinamide, NCGG401), that targets colony-stimulating factor 1 receptor (CSF1R). In this study, we present the first-in-human
-
Performance Characteristics of a New Generation 148-cm Axial Field-of-View uMI Panorama GS PET/CT System with Extended NEMA NU 2-2018 and EARL Standards J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Haiqiong Zhang, Chao Ren, Yu Liu, Xinchun Yan, Meixi Liu, Zhixin Hao, Haiqun Xing, Li HuoThe uMI Panorama GS PET/CT system is a new long-axial-field-of-view scanner featuring high sensitivity, time-of-flight (TOF) resolution, spatial resolution, and count rate performance. The aim of this study is to assess the PET system on the basis of the National Electrical Manufacturers Association (NEMA) NU 2-2018 and European Association of Nuclear Medicine Research Limited (EARL) standards. Methods:
-
MIRD Pamphlet No. 31: MIRDcell V4—Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Sumudu Katugampola, Jianchao Wang, Roger W. HowellRadiopharmaceutical cocktails have been developed over the years to treat cancer. Cocktails of agents are attractive because 1 radiopharmaceutical is unlikely to have the desired therapeutic effect because of nonuniform uptake by the targeted cells. Therefore, multiple radiopharmaceuticals targeting different receptors on a cell is warranted. However, past implementations in vivo have not met with
-
Improved Localization of Insulinomas Using 68Ga-NODAGA-Exendin-4 PET/CT J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Marti Boss, Olof Eriksson, Kirsi Mikkola, Annemarie Eek, Maarten Brom, Mijke Buitinga, Adrienne H. Brouwers, Irina Velikyan, Beatrice Waser, Saila Kauhanen, Olof Solin, Camille Marciniak, Barbro Eriksson, Jean-Claude Reubi, Cyrielle Aveline, Damian Wild, Francois Pattou, Jean-Noel Talbot, Johannes Hofland, Anders Sundin, Pirjo Nuutila, John Hermans, Martin GotthardtPrecise anatomic localization of insulinomas is crucial for surgical treatment. Current routine noninvasive imaging techniques, including CT, MRI, and 68Ga-DOTA-somatostatin analog (DOTA-SSA) PET/CT, have limited sensitivity. Endoscopic ultrasound is highly sensitive but invasive. In this prospective multicenter study, we compared the diagnostic accuracy of 68Ga-NODAGA-exendin-4 (exendin) PET/CT with
-
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Rong Rong Huang, Chunlai Zuo, Christine E. Mona, Adrien Holzgreve, Colm Morrissey, Peter S. Nelson, Lauren Brady, Lawrence True, Anthony Sisk, Johannes Czernin, Jeremie Calais, Huihui YeProstate-specific membrane antigen (PSMA) is a theranostic target for metastatic prostate cancer (PCa). However, castration-resistant PCa (CRPC) may lose PSMA expression after systemic therapy. Fibroblast activation protein (FAP), expressed by carcinoma-associated fibroblasts in various cancer types, including PCa, has the potential to be an alternative target. In this study, we evaluated FAP expression
-
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617 J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Ridvan Arda Demirci, Roman Gulati, Jessica E. Hawley, Todd Yezefski, Michael C. Haffner, Heather H. Cheng, Robert B. Montgomery, Michael T. Schweizer, Evan Y. Yu, Peter S. Nelson, Delphine L. Chen, Amir Iravani177Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but survival outcomes vary widely, and predictors of treatment responses are needed. This study investigated the role of total tumor volumes (TTVs) and new lesions (NLs) determined by LuPSMA SPECT/CT in early cycles to predict subsequent outcomes in a real-world practice
-
Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Mina Swiha, Sarennya Pathmanandavel, Nathan Papa, Zahra Sabahi, Sherrington Li, Alex Zheng, Sobia Khan, Maria Ayers, Shikha Sharma, Megan Crumbaker, Andrew Nguyen, Lyn Chan, Narjess Ayati, Louise Emmett[177Lu]Lu-prostate-specific membrane antigen (PSMA) is an effective treatment for metastatic castration-resistant prostate cancer (mCRPC). [177Lu]Lu-PSMA SPECT/CT 24 h after injection has shown potential as a response biomarker for [177Lu]Lu-PSMA therapy but is not convenient for patients. This study investigated 4-h [177Lu]Lu-PSMA SPECT/CT as an alternative to 24-h [177Lu]Lu-PSMA SPECT/CT for evaluation
-
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617 J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Miguel Muniz, Oliver Sartor, Jacob J. Orme, Regina M. Koch, Hana R. Rosenow, Ahmed M. Mahmoud, Jack R. Andrews, Adam M. Kase, Irbaz B. Riaz, Gokce Belge Bilgin, Matthew P. Thorpe, A. Tuba Kendi, Geoffrey B. Johnson, Praful Ravi, Eugene D. Kwon, Daniel S. ChildsIt is well known that patients with liver metastasis from metastatic castration-resistant prostate cancer have poor or only transient responses to many forms of systemic therapy. Data on outcomes after treatment with [177Lu]Lu-PSMA-617 (LuPSMA) are scarce. The VISION trial reports a hazard ratio for overall survival (OS) in the subgroup of patients with liver metastasis without disclosing the absolute
-
Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Ida Sonni, Adam B. Weiner, Sahith Doddipalli, Madhvi Deol, David Ban, Hye Ok Kim, Tristan Grogan, Preeti Ahuja, Nashla Barroso, Yang Zong, Priti Soin, Anthony Sisk, Johannes Czernin, William Hsu, Jeremie Calais, Robert E. Reiter, Steven S. RamanMultiparametric MRI (mpMRI) and prostate-specific membrane antigen (PSMA) PET/CT are complementary imaging modalities used in the presurgical evaluation of patients with prostate cancer (PCa). The purpose of this study was to characterize clinically significant PCa (csPCa) detected and not detected by PSMA PET/CT and mpMRI, focusing on tumors detected solely by PSMA PET/CT and overlooked by mpMRI.
-
Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Andreas Helisch, Clemens Kratochwil, Christian Kleist, Susanne Krämer, Juan Jose Rosales Castillo, Katharina Dendl, Hendrik Rathke, Isabelle von Goetze, Mathias Schreckenberger, Dirk Jäger, Thomas Lindner, Walter Mier, Frederik Giesel, Uwe Haberkorn, Manuel RöhrichRadiopharmaceutical therapies (RPTs) based on fibroblast activation protein (FAP) and FAP inhibitors (FAPIs) are a new option for progressive metastatic cancer in patients pretreated multiple times. To date, published in-human data refer to initial experiences with β-emitting 90Y- and 177Lu-based RPT. However, the short tumor retention time of FAPI ligands is considered a major limitation of FAPI RPT
-
Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Adriana Amerein, Christoph Maurer, Malte Kircher, Alexander Gäble, Anne Krebold, Andreas Rinscheid, Oliver Viering, Christian H. Pfob, Ralph A. Bundschuh, Lars Behrens, Arthur JAT Braat, Ansgar Berlis, Constantin LapaPeptide receptor radionuclide therapy (PRRT) is a treatment option for patients with advanced meningioma. Recently, intraarterial application of the radiolabeled somatostatin receptor agonists has been introduced as an alternative to standard intravenous administration. In this study, we assessed the safety and efficacy of intraarterial PRRT in patients with advanced, progressive meningioma. Methods:
-
Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Wei Huang, Min Cao, Yanfei Wu, You Zhang, Shuxian An, Xinbing Pan, Xinyuan Zhou, Hongda Shao, Yihui Guan, Gang Huang, Fabrizia Gelardi, Arturo Chiti, Fang Xie, Jianjun Liu, Weijun WeiImmuno-PET/CT imaging, a branch of molecular imaging, can noninvasively and specifically visualize biomarker expression across the body. Trophoblast cell surface antigen 2 (Trop2) is a pan-cancer biomarker and plays a crucial role in tumorigenesis through multiple signaling pathways. The study aims to develop and translate novel Trop2 single-domain antibody (sdAb) tracers for clinical use. Methods:
-
[18F]FDG and [68Ga]Ga-FAPI-04–Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Kerstin Michalski, Aleksander Kosmala, Philipp E. Hartrampf, Marieke Heinrich, Sebastian E. Serfling, Wiebke Schlötelburg, Andreas K. Buck, Alexander Meining, Rudolf A. Werner, Alexander WeichWe aimed to quantitatively investigate the prognostic value of PET-based biomarkers on [18F]FDG and [68Ga]Ga-fibroblast activation protein inhibitor (FAPI)-04 PET/CT in patients with highly aggressive neuroendocrine neoplasms (NENs) and to compare the visually assessed differences in uptake on both examinations with progression-free survival (PFS). Methods: In this single-center retrospective analysis
-
CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Xiang Zhou, Qianyun Wu, Wei Zhai, You Zhang, Yanfei Wu, Min Cao, Cheng Wang, Yihui Guan, Jianjun Liu, Fang Xie, Weijun WeiThe diagnosis and surveillance of clear cell renal cell carcinoma (ccRCC) remains a clinical challenge. The high and specific expression of the cluster of differentiation 70 (CD70) in ccRCC makes it a potential diagnostic and therapeutic target. Methods: We detected and analyzed CD70 expression in various renal cell carcinomas (RCCs) and normal kidneys using immunohistochemical staining. Two novel
-
Value of [68Ga]Ga-NYM046 PET/CT, in Comparison with 18F-FDG PET/CT, for Diagnosis of Clear Cell Renal Cell Carcinoma J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Kequan Lou, Jialiang Wang, Huihui He, Yanjuan Wang, Yuanyuan Mi, Wenjin Li, Liping Chen, Yu Zhang, Yong Mao, Jianguo Lin, Haitian Fu, Chunjing YuThis study aimed to investigate the diagnostic efficacy of [68Ga]Ga-NYM046 PET/CT in animal models and patients with clear cell renal cell carcinoma (ccRCC) and to compare its performance with that of 18F-FDG PET/CT. Methods: The in vivo biodistribution of [68Ga]Ga-NYM046 was evaluated in mice bearing OS-RC-2 xenografts. Twelve patients with ccRCC were included in the study; all completed paired [68Ga]Ga-NYM046
-
International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume–Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Vibeke K.J. Vergote, Gregor Verhoef, Ann Janssens, F.J. Sherida H. Woei-a-jin, Wies Deckers, Annouschka Laenen, Thomas Tousseyn, Daan Dierickx, Christophe M. DerooseBaseline metabolic tumor volume (MTV) is a promising prognostic marker in diffuse large B-cell lymphoma (DLBCL). We assessed the prognostic value of 4 novel metabolic risk scores in a real-life DLBCL cohort and compared them with the revised International Prognostic Index (IPI). Methods: We included a consecutive series of untreated DLBCL, not otherwise specified cases that were diagnosed in our hospital
-
[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Jelena Levi, Millie Das, Minal S. Vasanawala, Deepti Behl, Martin Pomper, Patrick M. Forde, Erica Nakajima, James Sayre, Bin Shen, Hilda Cabrera, Niko Del Mar, Michele Gullen, Michele Pierini, Laura Cox, Ojaswita Lokre, Timothy Perk, Hee-Don ChaeDespite the systemic impact of both cancer and the associated immune response, immuno-PET is predominantly centered on assessment of the immune milieu within the tumor microenvironment. The aim of this study was to assess the value of [18F]F-AraG PET imaging as a noninvasive method for evaluation of system-wide immune status of patients with non–small cell lung cancer before starting immunotherapy
-
Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate–Ribose) Polymerase-1–Targeted 18F-Fluorthanatrace PET in Breast Cancer J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Anthony J. Young, Austin R. Pantel, Mahsa Kiani, Robert K. Doot, Sina Bagheri, Daniel A. Pryma, Michael D. Farwell, Shihong Li, Hsiaoju Lee, Erin K. Schubert, Anthony Secreto, Samantha P. Zuckerman, Anupma Nayak, Hoon Choi, Sean Carlin, Angela DeMichele, David A. Mankoff, Rong Zhou, Robert H. Mach, Elizabeth S. McDonaldThe poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi) have demonstrated efficacy in ovarian, breast, and prostate cancers, but current biomarkers do not consistently predict clinical benefit. 18F-fluorthanatrace (18F-FTT) is an analog to rucaparib, a clinically approved PARPi, and is a candidate biomarker for PARPi response. This study intends to characterize 18F-FTT pharmacokinetics
-
Impact of 18F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Kai Jannusch, Lale Umutlu, Julian Kirchner, Nils-Martin Bruckmann, Janna Morawitz, Ken Herrmann, Wolfgang Peter Fendler, Ann-Kathrin Bittner, Oliver Hoffmann, Svjetlana Mohrmann, Eugen Ruckhäberle, Martin Stuschke, Werner Schmid, Frederik Giesel, Lena Häberle, Irene Esposito, Wilfried Budach, Johannes Grueneisen, Christiane Matuschek, Bernd Kowall, Andreas Stang, Gerald Antoch, Christian BuchbenderOur rationale was to investigate whether 18F-FDG PET/MRI in addition to (guideline-recommended) conventional staging leads to changes in therapeutic management in patients with newly diagnosed breast cancer and compare the diagnostic accuracy of 18F-FDG PET/MRI with that of conventional staging for determining the Union for International Cancer Control (UICC) stage. Methods: In this prospective, double-center
-
Precision Oncology in Melanoma: Changing Practices J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Sean C. Dougherty, William L. Flowers, Elizabeth M. GaughanOver the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis for metastatic melanoma was poor because of limited treatment options. However, after multiple landmark clinical trials displaying the efficacy of combined BRAF/MEK inhibition for BRAF-mutant melanoma and
-
Modeling PET Data Acquired During Nonsteady Conditions: What If Brain Conditions Change During the Scan? J Nucl. Med. (IF 9.1) Pub Date : 2024-12-01
Evan D. Morris, Gaelle M. Emvalomenos, Jocelyn Hoye, Steven R. MeikleResearchers use dynamic PET imaging with target-selective tracer molecules to probe molecular processes. Kinetic models have been developed to describe these processes. The models are typically fitted to the measured PET data with the assumption that the brain is in a steady-state condition for the duration of the scan. The end results are quantitative parameters that characterize the molecular processes
-
MIRD Pamphlet No. 30: MIRDfit—A Tool for Fitting of Biodistribution Time–Activity Data for Internal Dosimetry J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01
Lukas M. Carter, Juan Camilo Ocampo Ramos, Seval Beykan Schuerrle, Harry Marquis, Michael Lassmann, Wesley E. Bolch, Adam L. KesnerIn nuclear medicine, estimating the number of radioactive decays that occur in a source organ per unit administered activity of a radiopharmaceutical (i.e., the time-integrated activity coefficient [TIAC]) is an essential task within the internal dosimetry workflow. TIAC estimation is commonly derived by least-squares fitting of various exponential models to organ time–activity data (radiopharmaceutical
-
Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01
Maria C. Ferrández, Sandeep S.V. Golla, Jakoba J. Eertink, Sanne E. Wiegers, Gerben J.C. Zwezerijnen, Martijn W. Heymans, Pieternella J. Lugtenburg, Lars Kurch, Andreas Hüttmann, Christine Hanoun, Ulrich Dührsen, Sally F. Barrington, N. George Mikhaeel, Luca Ceriani, Emanuele Zucca, Sándor Czibor, Tamás Györke, Martine E.D. Chamuleau, Josée M. Zijlstra, Ronald BoellaardThe aim of this study was to validate a previously developed deep learning model in 5 independent clinical trials. The predictive performance of this model was compared with the international prognostic index (IPI) and 2 models incorporating radiomic PET/CT features (clinical PET and PET models). Methods: In total, 1,132 diffuse large B-cell lymphoma patients were included: 296 for training and 836
-
The Updated Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT 2.0) J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01
Robert J.H. Miller, Mark Lemley, Aakash Shanbhag, Giselle Ramirez, Joanna X. Liang, Valerie Builoff, Paul Kavanagh, Tali Sharir, M. Timothy Hauser, Terrence D. Ruddy, Mathews B. Fish, Timothy M. Bateman, Wanda Acampa, Andrew J. Einstein, Sharmila Dorbala, Marcelo F. Di Carli, Attila Feher, Edward J. Miller, Albert J. Sinusas, Julian Halcox, Monica Martins, Philipp A. Kaufmann, Damini Dey, Daniel SThe Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT) has been expanded to include more patients and CT attenuation correction imaging. We present the design and initial results from the updated registry. Methods: The updated REFINE SPECT is a multicenter, international registry with clinical data and image files. SPECT images were processed by quantitative software
-
Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01
Masatoshi Hotta, Grace Hyun J. Kim, Vilasinee Rerkpichaisuth, Pang Yu Teng, Wesley R. Armstrong, Giuseppe Carlucci, Magnus Dahlbom, Fereidoun Abtin, Shahrzad M. Lari, Gregory A. Fishbein, Johannes Czernin, Elizabeth R. Volkmann, S. Sam Weigt, Jeremie CalaisRecent studies have demonstrated promising results of fibroblast activation protein (FAP) inhibitor (FAPI) PET in prognosticating and monitoring interstitial lung diseases (ILDs). As a first step toward successful translation, our primary aim was to validate the FAPI PET uptake through immunohistochemistry in patients with advanced ILD who underwent lung transplantation after a FAPI PET scan. Methods:
-
Summary: Appropriate Use Criteria for the Use of Nuclear Medicine in Fever of Unknown Origin J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01
Christopher J. Palestro, Gad Abikhzer, Zvi Bar-Sever, Twyla Bartel, Rebecca Brady, Erin E. Grady, Ora Israel, Sanjay K. Jain, Sheetal Kandiah, Machaba M. Sathekge, Barry L. ShulkinThe diagnostic work-up of patients with fever of unknown origin (FUO) begins with a thorough history and physical examination, complete blood count with differential, chest x-ray, urinalysis and culture, electrolyte panel, liver enzymes, erythrocyte sedimentation rate, and C-reactive protein level. Additional imaging procedures, including nuclear medicine tests, are generally used as second-line procedures
-
Validation of a Simplified Tissue-to-Reference Ratio Measurement Using SUVR to Assess Synaptic Density Alterations in Alzheimer Disease with [11C]UCB-J PET J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01
Juan J. Young, Ryan S. O’Dell, Mika Naganawa, Takuya Toyonaga, Ming-Kai Chen, Nabeel B. Nabulsi, Yiyun Huang, Emma Cooper, Alyssa Miller, Jessica Lam, Kara Bates, Audrey Ruan, Kimberly Nelsen, Elaheh Salardini, Richard E. Carson, Christopher H. van Dyck, Adam P. MeccaSimplified methods of acquisition and quantification would facilitate the use of synaptic density imaging in multicenter and longitudinal studies of Alzheimer disease (AD). We validated a simplified tissue-to-reference ratio method using SUV ratios (SUVRs) for estimating synaptic density with [11C]UCB-J PET. Methods: Participants included 31 older adults with AD and 16 with normal cognition. The distribution
-
Evaluation of Fibroblast Activation Protein Expression Using 68Ga-FAPI46 PET in Hypertension-Induced Tissue Changes J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01
Jung Woo Byun, Jin Chul Paeng, Young Ju Kim, Seung-Pyo Lee, Yun-Sang Lee, Hongyoon Choi, Keon Wook Kang, Gi Jeong CheonChronic hypertension leads to injury and fibrosis in major organs. Fibroblast activation protein (FAP) is one of key molecules in tissue fibrosis, and 68Ga-labeled FAP inhibitor-46 (FAPI46) PET is a recently developed method for evaluating FAP. The aim of this study was to evaluate FAP expression and fibrosis in a hypertension model and to test the feasibility of 68Ga-FAPI46 PET in hypertension. Methods:
-
Preclinical Investigation of [212Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01
Amal Saidi, Tania A. Stallons, Amy G. Wong, Julien J. TorgueThe role of gastrin-releasing peptide receptor (GRPR) in various diseases, including cancer, has been extensively studied and has emerged as a promising therapeutic target. In this study, we successfully achieved the use of [212Pb]Pb-DOTAM-GRPR1, comprising the α-particle generator, 212Pb, combined with a GRPR-targeting peptide, GRPR1, in a prostate cancer model. Methods: Pharmacokinetics, toxicity
-
Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01
Helena Koniar, Luke Wharton, Aidan Ingham, Ana Paulina Morales Oliver, Helen Merkens, Cristina Rodríguez-Rodríguez, Peter Kunz, Valery Radchenko, Hua Yang, Arman Rahmim, Carlos Uribe, Paul Schaffer226Ac (t1/2 = 29.37 h) has been proposed as a theranostic radioisotope leveraging both its diagnostic -emissions and therapeutic α-emissions. 226Ac emits 158 and 230 keV -photons ideal for quantitative SPECT imaging and acts as an in vivo generator of 4 high-energy α-particles. Because of these nuclear decay properties, 226Ac has potential to act as a standalone theranostic isotope. In this proof-of-concept
-
Routine Use of [64Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans J Nucl. Med. (IF 9.1) Pub Date : 2024-11-01
Esben Andreas Carlsen, Mathias Loft, Camilla Bardram Johnbeck, Ulrich Knigge, Seppo W. Langer, Jann Mortensen, Lotte Enevoldsen, Peter Oturai, Andreas KjaerThe role of somatostatin receptor (SSTR) PET/CT, using 68Ga-based tracers or [64Cu]Cu-DOTATATE (64Cu-DOTATATE), in the management of patients with neuroendocrine neoplasm (NEN) is guided by appropriate use criteria (AUC). In this study, we performed systematic analyses of referral patterns and image findings of routine 64Cu-DOTATATE PET/CT scans to support AUC development. Methods: We included all